Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.10 (-0.38%)
Bid:
26.50
Ask:
26.90
Spread: 0.40 (1.509%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Form 8 (OPD) EKF Diagnostics Holdings plc

7 Sep 2015 07:00

RNS Number : 1982Y
JinJing Group Ltd
07 September 2015
 



 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Jinjing (Group) Co., Ltd.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

OFFEREE - EKF Diagnostics Holdings plc

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

N/A

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

GBP 0.01 GB0031509804

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0%

0

0%

(2) Cash-settled derivatives:

 

0

0%

0

0%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0%

0

0%

 

TOTAL:

0

0%

0

0%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

N/A

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

none

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

none

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

7 September 2015

Contact name:

Nicholas Page

Telephone number:

020 7187 2000

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEUGURABUPAGQC
Date   Source Headline
20th May 20265:41 pmRNSLong Term Incentive Plan Award
19th May 202612:24 pmRNSResult of AGM
19th May 20267:00 amRNSAGM statement & positive Q1 trading update
27th Apr 20267:00 amRNSBoard Changes
24th Apr 20264:43 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSAcquisition of assets from Beep Insights
10th Apr 20269:12 amRNSShare Buyback
8th Apr 20262:33 pmRNSShare Buyback
7th Apr 20261:09 pmRNSShare Buyback
2nd Apr 20267:00 amRNSShare Buyback
31st Mar 20265:59 pmRNSShare Buyback
24th Mar 20267:00 amRNSFull year results
20th Mar 202611:25 amRNSShare Buyback
19th Mar 202611:20 amRNSShare Buyback
19th Mar 20267:00 amRNSHolding(s) in Company
18th Mar 20269:58 amRNSShare Buyback
6th Mar 20267:00 amRNSShare Buyback
5th Mar 20267:00 amRNSNotice of Results
3rd Mar 20267:00 amRNSThree-year Hematology purchasing agreement
2nd Mar 20263:30 pmRNSTotal Voting Rights
27th Feb 20267:00 amRNSShare Buyback
19th Feb 20267:00 amRNSShare Buyback Programme
2nd Feb 20267:00 amRNSShare Buyback & Completion of Buyback Programme
30th Jan 20267:00 amRNSShare Buyback
29th Jan 20267:00 amRNSShare Buyback
28th Jan 202611:41 amRNSShare Buyback
27th Jan 20267:00 amRNSFY 2025 Trading Update
15th Jan 20267:00 amRNSShare Buyback
14th Jan 202611:43 amRNSShare Buyback
14th Jan 20269:37 amRNSShare Buyback
12th Jan 20269:45 amRNSShare Buyback
9th Jan 20265:00 pmRNSShare Buyback
8th Jan 20269:40 amRNSShare Buyback
6th Jan 20266:03 pmRNSShare Buyback
2nd Jan 202610:23 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
31st Dec 202510:45 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
30th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
29th Dec 20257:00 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
24th Dec 202510:43 amRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
23rd Dec 20255:23 pmRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
22nd Dec 202511:10 amRNSShare Buyback
16th Dec 20251:57 pmRNSShare Buyback
16th Dec 20257:00 amRNSExecutive Chair share purchase
8th Dec 20257:00 amRNSCancellation of Treasury Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.